Oncurious to Buy VIB’s Immun-Oncology Portfolio
With this acquisition, Oncurious, a Belgium-based biotechnology company, will gain a pipeline of immune-oncology drug candidates.
On Sep. 1, 2017, Oncurious, a Belgium-based biotechnology company focused on oncology, announced an agreement with VIB, a life sciences research institute also based in Belgium, to acquire exclusive licenses to a portfolio of five next-generation immuno-oncology assets. These assets originated from work done in the VIB-KULeuven and VIB-VUB laboratories.
The acquisition broadens Oncurious’ clinical development activities in orphan pediatric oncology indications. VIB Discovery Sciences will lead the pre-clinical development of these new projects. Under the agreement, VIB will increase its stake in Oncurious, with ThromboGenics, a Belgium-based biotechnology company, remaining the majority shareholder. VIB will also receive a royalty on future sales of any of these assets. ThromboGenics invests an additional EUR 2.1 million (US$2.5 million) in Oncurious.
Oncurious is currently conducting a Phase I/IIa clinical trial to evaluate a drug candidate, TB-403, in treating medulloblastoma, in collaboration with BioInvent, a Swedish research-based pharmaceutical company. TB-403 is a humanized monoclonal antibody against placental growth factor (PLGF). PLGF is expressed in several types of cancer, including medulloblastoma.
Source: Oncurious
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
